



Europäisches Patentamt
European Patent Office
Office européen des brevets

⑪ Publication number:

0 112 58
A2

⑫

EUROPEAN PATENT APPLICATION

㉑ Application number: 83307220.0

㉓ Int. Cl.³: A 61 L 15/01, A 61 K 9/06,
A 61 K 31/02, A 61 K 31/025

㉒ Date of filing: 25.11.83

㉔ Priority: 26.11.82 US 444850

㉕ Applicant: CHILDREN'S HOSPITAL MEDICAL CENTER,
Elland and Bethesda Avenues, Cincinnati
Ohio 45229 (US)

㉖ Date of publication of application: 04.07.84
Bulletin 84/27

㉗ Inventor: Clark, Leland C., Jr., 218 Greendale Avenue,
Cincinnati Ohio 45220 (US)

㉘ Designated Contracting States: BE CH DE FR GB IT LI
NL SE

㉙ Representative: Allam, Peter Clerk et al, LLOYD WISE,
TREGEAR & CO. Norman House 105-109 Strand, London
WC2R 0AE (GB)

㉚ **Extraocular method and devices for treating the eye.**

㉛ Extraocular ophthalmic preparations or devices useful as therapeutic, diagnostic lubricating or protective agents are disclosed. Perfluorocarbon films or gels are employed extraocularly as contact lenses. Liquid perfluorocarbons and substituted derivatives are the active components of the ophthalmic preparations. The neat perfluorocarbon liquids are not aqueous, wherefore, isotonicity and pH need not be considered in their preparation. Liquid sterility may be maintained without the addition of preservatives. Cornea and conjunctiva surfaces are provided with greater amounts of oxygen when the perfluorocarbon liquids are employed as eye drops. Transparent contact lenses having oxygen permeable properties are provided by the extraocular perfluorocarbon films or discs. Emulsions of perfluorocarbons in water are also suitable for all of the above uses and as carriers for drugs, antibiotics, hormones and therapeutic agents.

EP 0 112 658 A2

1-

TITLE: EXTRAOCULAR METHODS AND DEVICES FOR
TREATING THE EYE

Background of the Invention

Ophthalmic preparations are administered into the eye for treating a wide variety of ocular disorders. Usually, these preparations are sterile products designed for either topical application onto the internal eyelid or instillation into the cul-de-sacs strategically positioned between the eyeball (cornea and bulba conjunctiva) and eyelids (palpebral conjunctiva).
5 Ophthalmic preparations may also be prepared in the form of an injection. At the present time, the following are the most common methods of delivering therapeutic substance to the eye: by the mechanism of some sort of vehicle or delivery system to the surface of the eye comprising ocular solutions, suspensions, ointments, gels and inserts; and by either periocular or systemic injections.
10 If there are any diseases within the eye to be treated pharmaceutically, however, the obviously safe and most preferred method of providing that treatment would be by extraocular topical application.
15 Such disorders include dry eye syndrome caused by keratoconjunctivitis sicca, tear abnormalities, atrophy of the lacrimal gland, ocular pemphigoid, chemical burns, chronic keratoconjunctivitis, corneal epithelial diseases (corneal ulcers, recurrent corneal erosion and
20 marginal ulcers), and corneal vascularization due to corneal injury, infection or transplantation.
25

Notwithstanding the safety and apparent convenience of topical ophthalmic preparations, several have significant disadvantages which adversely affect 30 their suitability and efficacy. Some of the disadvantages are brief duration in the cul-de-sacs, irritation, burning or stinging sensations, stickiness, and discomfort, all of which can be attributed to the

vehicle, preservatives, inserts or drug itself.

Because of these disadvantages, patients may not even comply with their doctor's advice for using them.

Presently, all ophthalmic preparations,

5 including those commonly referred to as "eye drops",
are required to be sterile before their instillation
into the eye. In most ophthalmic preparations,
sterility is achieved and maintained by incorporating
preservatives. Preservatives, however, are known to
10 adversely affect the surface structure of the corneal
epithelium and disrupt the microvilli which are
necessary for the cornea to retain the tear film layer.
Thus, the mucin layer of the tear film cannot be
properly adsorbed onto the abnormal microvilli of the
15 corneal and conjunctiva surfaces. Without adsorption
of the mucin layer onto the corneal and conjunctiva
surfaces, the wetting of these surfaces by aqueous tear
film layer is prevented.

In addition to the sterility requirement, eye

20 drops, comprising suspensions and solutions, are rapidly
eliminated from the cul-de-sacs by the naso-lacrimal
drainage system. As a result of their aqueous
properties and low specific gravity, drops are miscible
with the secretory liquids of the eye subjecting them
25 to a faster rate of expulsion by way of the blinking
mechanism. Unfortunately, their persistence in the
cul-de-sacs is limited thereby significantly
compromising suitability and efficacy. Thus, to
achieve therapeutic results, ophthalmic eye drops
30 require frequent administration. Because of the
physical properties of suspensions, they tend to remain
longer in the cul-de-sacs than solutions. Nevertheless,
particles are dispersed throughout suspensions which are
severely irritating to the corneal and conjunctiva
35 surfaces.

Ophthalmic ointments and gels also cause undesirable effects when applied to the internal eyelid. Upon application, they produce a film over the corneal and conjunctiva surfaces blurring vision while usually failing to deliver a uniform dose. Moreover, they may interfere with the preocular tear film precluding its attachment to the corneal and conjunctiva surfaces.

Periocular and systemic injections require an ophthalmologist not only to administer but to monitor the drug. Injections tend to cause the patient a great deal of pain and discomfort, anxiety, and inconvenience. Eye inserts provide a delivery system that maintains a low but uniform and constant delivery of a drug. Since the drug is delivered for the duration, frequent administration, as with drops, is not necessary. The major disadvantages associated with ocular inserts involve unnoticed loss of the insert from the eye, slippage of the insert into the area of sight, rupturing of the insert's membrane subjecting the delicate structures of the eye to excessive medication, possible tachyphylaxis, and structural changes in the ciliary muscle resulting from the constant exposure to the drug. Furthermore, there is some degree of manual dexterity required of the patient to position the insert therapeutically and strategically correct.

In contact lens wear, injury to the corneal epithelium evolves as a direct consequence from the juxtaposition of the contact lens with the corneal surface. Because contact lenses are required to be durable and transparent, many of the materials presently available for their manufacture are practically impermeable to oxygen and carbon dioxide as well as other small molecules. The problem observed with contact lenses manufactured from these materials relates to recurrent corneal erosion and hypoxia. That is,

when a contact lens is positioned over the cornea, insufficient oxygen and carbon dioxide will diffuse through it, thereby irritating as well as precluding normal gaseous exchanges of the cornea. The net effect
5 is to cause lack of oxygen and irritation resulting in superficial vascularization and opacification of the cornea. Thus, there is a need for an oxygen permeable contact lens which allows diffusion of oxygen at a high rate and is sterilizable by heating in a steam autoclave
10 or by other harsh chemical methods.

With respect to corneal epithelial disease, eg corneal ulcers and marginal corneal ulcers, there is a breakdown of the epithelial barrier which may result in infectious diseases and chronic recurrent breakdowns.
15 The cornea, due to these disorders, will increase in hydration and loss of transparency. Thus, there is a need for proper ophthalmic preparations that can promote rapid and proper healing of such diseases to avoid formation of corneal scars or opacities. Corneal
20 transplantation or repair is indicated when the cornea has become opaque, infiltrated, or diseased. Because the healing process, as stated above, results in corneal opacification and scars, normal vision can be partially or totally obstructed. In general, corneal
25 transplantation or repair increases hydration while decreasing oxygenation of the cornea. Thus, an ingrowth of vessels is usually seen within the cornea after repair or transplantation responding to the corneal scar tissue, increase in hydration and lack of oxygen. Unfortunately,
30 corneal repair or transplantation, as with corneal epithelial disorders, can occlude normal vision.

It has heretofore been known to immerse experimental animals in liquid perfluorocarbons saturated with oxygen and the experimental animal is actually
35 capable of breathing the liquid. For instance, in 1966,

Leland C. Clark, Jr., the inventor herein, and his coworker F. Gollan, published such matters in Science 152, 1755-1756 (1966). In addition, photographs of a mouse breathing a liquid perfluorocarbon saturated with 5 oxygen are provided in Angewandte Chemie, 1978, pp 621-700 at p. 622. During such experiments, the eye of the experimental animal was exposed to a perfluorocarbon liquid, however, there was no appreciation or intention of treating a disorder of the 10 eye of the experimental animal with such perfluorocarbon liquid. Accordingly, to applicant's knowledge herein, heretofore there has been no knowledge or disclosure of treating disorders of the eye by the external administration of perfluorocarbons.

15 It is apparent from the above brief overview of various ophthalmic preparations or devices for the eye in pathological processes and the current state of knowledge that there are vital needs for more suitable, efficacious and advantageous extraocular ophthalmic 20 preparations.

Summary of the Invention

Perfluorocarbons and substituted derivatives thereof have been found useful as extraocular ophthalmic preparations or devices, ie preparations or devices for 25 the treatment of disorders of the eye. Perfluorocarbon films or gels are suitable for use as oxygen permeable contact lenses which allow diffusion of oxygen at a high rate and which may be sterilized by conventional techniques. Liquid perfluorocarbons and substituted 30 derivatives thereof have been found to be useful as a therapeutic agent or vehicle in extraocular ophthalmic preparations. These liquids act as lubricating, wetting or protective agents, as well as vehicles for other substances or drugs. These liquids will also 35 remain within the cul-de-sacs for greater periods of time since they have high specific gravities. In their

pure state, these liquids are not aqueous, wherefore isotonicity and pH do not need to be considered. Most fluorocarbon neat liquids have a refractive index near that of the aqueous, vitreous and tears. Moreover, 5 preservatives are not required to be incorporated into such liquids to maintain sterility. Corneal and conjunctiva surfaces, when treated with such liquids, are provided with greater amounts of oxygen because of high oxygen diffusion properties of the perfluorocarbons.

10 This invention is directed to the use of perfluorocarbon liquids and substituted derivatives thereof in extraocular ophthalmologic preparations. Perfluorocarbons have been found to be advantageous agents when instilled extraocularly into the eye as well 15 as a possible vehicle for other drugs and agents. The hydrophobic and lipophobic properties of these liquids have been found particularly useful as extraocular agents. Perfluorocarbon liquids have been instilled extraocularly into the eye of an experimental animal as 20 well as a human to function as lubricants or wetting solutions. They have been proven to be useful ophthalmic solutions, and the eyes of experimental animals or humans treated extraocularly with this liquid maintained normal vision and demonstrated no adverse 25 effects. Furthermore, the high specific gravity of the perfluorocarbon liquids permits their retention within the cul-de-sacs for a greater period of time. These and other remarkable discoveries will become further understood in the details which follow herein below.

30 The perfluorocarbon liquids preferably employed are transparent or light transmissive, inert, and remain viscous indefinitely. This invention is predicated in part upon the discovery that such perfluorocarbon liquids are ideal in extraocular preparations. Moreover, they 35 dissolve oxygen and carbon dioxide extremely well, and can be sterilized by autoclaving. Thus, these liquids

are comprised of unusual chemical and physical properties endowing them with unique, unexpected and advantageous uses in extraocular ophthalmic preparations. Another important discovery involved in this invention is that 5 these perfluorocarbons can be instilled into the cul-de-sacs and will remain therein for greater periods of time because of their greater density and immiscibility with aqueous media. Also, it is found that upon blinking, a microemulsion of the perfluorocarbon liquid may develop 10 within the lipid layer of the preocular tear film providing significant lubricating and wetting properties for the corneal and conjunctiva surfaces. Remarkably, these "microemulsions" remained in contact with the external surfaces of the eye for a substantial period of 15 time. Finally, the external surface of the eye will be better oxygenated because of the perfluorocarbon's high diffusion properties for oxygen and carbon dioxide.

In another feature of the invention, perfluorocarbon films, gels or liquids can be ideally 20 employed in contact lens wear, corneal epithelial disease, infection, corneal transplantation and/or repair, or as a vehicle. For instance, in the case of contact lenses or prostheses, perfluorocarbon film or gel provides an oxygen permeable lens which is 25 transparent, will diffuse oxygen at a high rate and can be sterilized by autoclaving or other harsh chemical methods. In another embodiment of this feature of the invention, for instance, the liquids will enhance oxygenation of the cornea and lubricate the epithelial 30 surface to reduce adverse side effects associated with the contact lens use. In addition, the liquids can be applied as a protective agent in corneal epithelial diseases to prevent infection and chronic recurrent epithelial breakdowns. In corneal repair, 35 transplantation or disease, the liquids enhance oxygenation of the corneal tissue and decrease hydration

thereby reducing superficial vascularization, scar tissue and opacities. As a vehicle, the liquids can deliver pharmaceutical agents to treat extraocular or intraocular disorders.

5 As indicated above, in the broader sense a contact lens is a prosthesis which may be provided in accordance with the principles of this invention. Such a prosthesis can be fabricated by conventional means so as to have conventional shapes, sizes and
10 configurations, as suited for the purpose which the prosthesis is to serve, all as well known to those skilled in the art of extraocular prostheses.

In the specific case of a contact lens, the prosthesis is utilized as a corrective measure for
15 optical accuity. The contact lenses of the present invention may be fabricated from the perfluorocarbons in solid or gel form, using techniques well known in the art of manufacturing contact lenses from polymeric materials in solid or gel form. For example, the
20 contact lenses may be made by grinding "buttons" of the solid perfluorocarbon material, or by directly casting the perfluorocarbon material into suitably configured molds.

In other instances, such a prosthesis can be
25 utilized therapeutically as a "bandage", for instance. A bandage will act to permit movement of medicinal fluids through the lens or prosthesis to the eye, as well as under the lens or prosthesis. The bandage will further increase the duration of effect and possibly the
30 degree of effect from given quantities of drug. The therapeutic use of such a bandage can be employed in disorders such as edema, epithelial erosion and defects, exposure, irregular cornea, dry eye syndrome, glaucoma, and herpes simplex keratitis. Upon highly perforating
35 a fluorocarbon contact lens, for example with perforations of from 10-100 microns in size, it may

serve as a means for holding liquid perfluorocarbon to prevent dry eye syndrome. In yet another embodiment, the prosthesis may be employed for cosmetic purposes such as changing the color of the eye.

5 A particular advantage of the present extraocular prostheses is that, in many instances at least, the solid or gel state of the perfluorocarbon provides an essential oxygen transfer capability which is lacking in many conventional extraocular prostheses.

10 Thus, for example, contact lenses fabricated from the perfluorocarbons can possess sufficient permeability to oxygen to satisfy the oxygen requirements of the human eye.

Detailed Description of the Invention

15 The perfluorocarbons and any derivatives thereof suitable for use in this invention are from the class of either solids, liquids, emulsions and gels. The term "solids", as used herein, means other fluorocarbons which in their normal state are solids, neither liquids 20 or gases, or may be fabricated into solids such as films, gels, discs, or the like, and suitable for use extraocularly in accordance with the principles of this invention. The term "liquids", as used herein, is a comprehensive designation incorporating compounds that 25 are in a state neither solid or gaseous such as liquids, suspensions, emulsions and gels. The term "perfluorocarbon" means a "cyclic" or "acyclic" compound of carbon, whereas the term "substituted derivatives thereof" characterizes substituted perfluorocarbons with chemical 30 elements within their structures such as oxygen, nitrogen and bromine, etc. The term perfluorocarbon also includes polymers such as polyfluoroethylene, polyfluoropropylene, polyfluoroethylene-propylene, or other polyfluorohydrocarbons. It should also be noted 35 that the term "perfluorocarbon" denotes substitution of all hydrogen atoms, or substantially all, attached to

the carbon atom chain or ring and any carbon side groups with fluorine. It is conceivable in the manufacture of such compounds that minor amounts of substantially fluorinated derivatives may be mixed with completely 5 fluorinated compounds. This is permissible providing that the lack of complete replacement of all hydrogens does not affect the essential characteristics of the liquid perfluorocarbons of this invention, particularly when active hydrogens critically enhance the toxicity of 10 the compounds. Perfluoropolymers such as E3 or E4, identified hereinafter, do have one hydrogen, but are still satisfactory. Among the perfluorocarbon compounds which may be employed are polyfluoroethylene, polyfluoropropylene, polyfluoroethylene-propylene 15 copolymer, perfluorotributylamine (FC47), perfluoro-decalin (PP5), perfluorotetrahydrofuran (FC80), perfluoroether (PID) $[(CF_3)_2CFOCF_2(CF_2)_2CF_2OCF(CF_3)_2]$, perfluoroether (PIID) $[(CF_3)_2CFOCF_2(CF_2)_6CF_2OCF(CF_3)_2]$, CF_3 20 perfluoropolymer (E3) $[CF_3CHF(OCF_2CF)_2OCF_2CF_2CF_3]$, CF_3 perfluoropolymer (E4) $[CF_3CHF(OCF_2CF)_3OCF_2CF_2CF_3]$, perfluoroetherpolymer (Fomblin Y/01), perfluorododecane, 25 perfluorobicyclo[4.3.0]nonane, perfluorotrimethylcyclohexane, perfluoroisopropylcyclohexane, perfluoroendo-tetrahydrodicyclopentadiene, perfluoroadamantane, perfluoroexo-tetrahydrodicyclopentadiene, perfluorobicyclo[5.3.0.]decane, perfluorotetramethylcyclohexane, 30 perfluorool-methyl-4-isopropylcyclohexane, perfluoro-n-butylcyclohexane, perfluorodimethylbicyclo[3.3.1.]nonane, perfluoro-1-methyl adamantane, perfluoro-1-methyl-4-t-butylcyclohexane, perfluoro-decahydroacenaphthene, perfluorotrimethylbicyclo[3.3.1.]nonane, perfluoro-n-undecane, perfluorotetradecahydrophenanthrene, 35 perfluoro-1,3,5,7-tetramethyladamantane, perfluorododecahydrofluorene, perfluoro-1,3-dimethyl adamantane,

perfluoro-n-octylcyclohexane, perfluoro-7-methyl
bicyclo[4.3.0.]nonane, perfluoro-p-diisopropylcyclo-
hexane, and perfluoro-m-diisopropylcyclohexane,
perfluorooctyl bromide, and perfluoro 1-bromobutyliso-
5 propyl ether.

Where perfluorocarbon films, gels, discs or
solids are employed as the extraocular preparation or
device as in the case of a contact lens, it is preferred
to use a transparent film or gel and for this purpose it
10 has been found that a duPont TEFLON FEP fluorocarbon
film which is a completely fluorinated ethylene-
propylene copolymer offers transparency and oxygen
permeability suitable for this purpose. It is to be
understood that perfluorocarbon liquids of this
.15 invention may be formed of "neat" perfluorocarbon liquids,
emulsions, suspensions or solutions of perfluorocarbons
in mixture with themselves or other solvents. For
instance, perfluoro-1,3-dimethyl adamantane is normally
a solid but in mixture with perfluorotrimethylbicyclo-
20 .-[3.3.1.]nonane a liquid is formed, ie, DAWN. The neat
liquids or polymers are preferred because of their
inertness and non-aqueousness. Also, when the
perfluorocarbon liquids are emulsified in water,
sometimes milky or even somewhat clear or transparent
25 liquids, emulsions, gels or solutions might result which
may be suitable for use in this invention. It is noted
here that the gels which may be employed in the present
invention are believed to be novel per se. Such gels
may be prepared by conventional techniques, eg by
30 emulsifying the perfluorocarbon liquids in water using
appropriate surfactants, in suitable amounts.

In extraocular ophthalmic preparations or
devices, solid, gel or fluid transparency is preferred,
but even somewhat milky solids or fluids may be used.
35 In the case of solids or gels, any perfluorocarbon or
substituted perfluorocarbon which is inert and nontoxic

may be employed as a solid, gel or similar form in an extraocular ophthalmic preparation or device for the treatment of eye disorders in accordance with the principles of this invention. In brief, then, the
5 nature of the "liquid" state may include pure liquid perfluorocarbon, emulsions, solutions, suspensions, etc., of perfluorocarbon compounds in other liquid mediums. Incorporated herein by reference, therefore, are
10 emulsions or suspensions of perfluorocarbons disclosed in U.S. Patents 3,911,138 and 4,105,798 as suitable liquids for use in this invention.

Perfluorocarbons are capable of being synthesized by well known chemical or electrochemical processes. In the case of perfluorocarbon polymers,
- 15 any fluorinated polyolefin polymers or copolymers, and derivatives thereof are included which are available and would be suitable for use in accordance with the principles of this invention. Accordingly, in its broadest sense, the term perfluorocarbon is employed in
20 this invention for extraocular ophthalmic devices or preparations and is intended to cover such polymeric fluorocarbons and other perfluorocarbons in order to obtain the advantageous results of this invention.
Also, in the case of liquid perfluorocarbons, the
25 chemical processes yield fairly pure substances of known structure, having well defined boiling points. Whereas the electrochemical processes tend to yield a mixture of isomers, the liquids have well defined boiling points.
With respect to gas chromatography, the liquid is
30 capable of being well defined by either the packed or capillary column procedure. The standard to define each compound in gas chromatography is prepared as follows: 2 microliters of neat liquid are added to 120 milliliters of air in a sealed bottle and allowed to
35 vaporize producing a stock standard; upon vaporization, 120 microliters of the vapor from the stock standard are

0112658

13-

added to another 120 milliliters of air in a sealed bottle producing the working standard; the sample measured by the procedure is withdrawn from the working standard, thus, a typical sample will contain 16.7 pico
5 liters of perfluorocarbon per milliliter of standard; however, in the capillary column procedure, the sample is split into a ratio of 23:1, therefore, only 1/23 of the sample is actually measured. As indicated in
10 Table II, the retention time is highly definitive of the liquid used in this invention. Moreover, the capillary procedure is more specific than the packed column procedure by defining additional characteristic peaks of the compound. Thus, a more precise definition
15 of the compound can be had with the capillary column procedure as exemplified for perfluoro 1-methyldecalin in the following TABLE.

0112658

14-

TABLE I

Gas Chromatography*

	Packed Column**	Capillary Column***
--	-----------------	---------------------

<u>Set Up</u>	[16.7 p1/ml]****	[16.7 p1/ml]****
Standard	[0.001Y full scale	[0.001Y full scale
Recorder	100°C	37°C
Column Temperature	250°C	250°C
Detector Temperature	150°C	150°C
Injector Temperature	40 ml/min	40 ml/min
N ₂ Gas Flow	---	23:1
Split	2.5 cm/min	2.5 cm/min
Recorder Speed		
<u>Compound</u>		
PP9 (perfluoro 1-methyldecalin)		
	8	4
Attenuation	50 mcL	100 mcL
Sample	3	7
Peaks		
Retention Time		
Peak ₁	124.8 sec	211.2 sec
Peak ₂	136.8 sec	240 sec
Peak ₃	196.8 sec	340.8 sec
Peak ₄	---	362.4 sec
Peak ₅	---	379.2 sec
Peak ₆	---	391.2 sec
Peak ₇	---	403.2 sec

* Autek 300 Gas Chromatograph instrument

** Supelco, Inc. Packed Column

*** Scientific Glass Engineering Capillary Column

**** p1/ml = picoliters/milliliter

A preferred perfluorocarbon, in the case of an extraocular ophthalmic device is known in the trade as TEFLON FEP-fluorocarbon, supplied by duPont which is a completely fluorinated ethylene-propylene copolymer.

5 This film has a balance of important properties for extraocular ophthalmic lens use such as transparency, inertness, and oxygen permeability. Preferred liquid perfluorocarbons, exemplified by perfluoro-1-methyl decalin, all have in common a high solubility in

10 oxygen and carbon dioxide, inertness, high density, and transparency. They are suitable for instillation into the eye as extraocular ophthalmic preparations and in the treatment of ophthalmologic disorders. A particular perfluorocarbon or a mixture of perfluoro-

15 carbons falling within the family of liquids exemplified by the above derivative may be used according to the principles of our invention. One main property generic to the preference of the solids, gels or liquids according to this invention over other fluoro-containing

20 compounds is their chemical structure rendering them RES-phobic. These compounds have been defined in U.S. Patent 3,911,138 as "perfluorocyclocarbons", especially perfluoro (methylcyclohexane), perfluoro-1-methyldecalin [also known as perfluoro(decahydro-1-methylnaphthalene)],

25 perfluoro (1,3-dimethylcyclohexane), perfluoro (decahydronaphthalene), and perfluoro (decahydromethyl-naphthalene), or mixtures thereof, perfluorinated bicyclononane, perfluorinated bicyclooctane, perfluorinated adamantane hydrocarbon, perfluoromethyl-

30 adamantane and perfluorodimethylbicyclo[3.3.1.]nonane, perfluorodimethyladamantane and perfluorotrimethylbicyclo[3.3.1.]nonane, perfluorotetrahydrodicyclo-pentadiene and perfluorobicyclo[5.3.0.]decane,

35 perfluorotetrahydrodicyclopentadiene, perfluorinated bicyclononane, perfluorinated bicyclooctane, perfluorinated adamantane hydrocarbon, perfluoromethyl-

adamantane and perfluorodimethylbicyclo[3.3.1]nonane, perfluorodimethyladamantane and perfluorotrimethylbicyclo[3.3.1.]nonane, and perfluorotetrahydrodicyclopentadiene and perfluorobicyclo[5.3.0]decane. RES-phobic perfluorinated solids, gels or liquids tend to accumulate less in the bodies of animals, principally in the liver, and to a lesser extent in the spleen and kidneys. This is significant because such compounds will not become fixed indefinitely within the cells of the organ. There is another property associated with this class of perfluorocarbons that is preferentially utilized when they are introduced into the eye. A perfluorocarbon or a mixture thereof is preferably employed having a vapor pressure within the range of about 1 to about 25 torrs at about 35°C. Thus, such liquids or mixtures are not only RES-phobic, but upon escaping the cell expediently, they will not cause adverse gas collection in the tissue of animals.

In its broadest application, the invention involves the extraocular employment of a perfluorocarbon either in a solid, gel or liquid state as an extraocular ophthalmic preparation or device to treat ocular disorders. In one application of the invention, contact lenses may be fabricated from perfluorocarbons, as mentioned above, in order to treat ocular disorders of myopia or hyperopia, for instance. In another instance, the invention involves the instillation of liquid perfluorocarbons into the eye as extraocular ophthalmologic preparations to treat ocular disorders. The liquid can be placed or instilled in the eye extraocularly by a device comprising a container for the liquid and means for dispensing controlled amounts of the liquid from the container. Such a device can, for example, take the form of an eye dropper such as a dropper bottle, or a separate dropper or pipette may be employed. In this connection, due to the specific

gravity, low surface tension and high vapor pressure of the specific perfluorocarbon liquids, it may be necessary that the means for dispensing the liquid extraocularly onto the eye in a controlled manner should provide a fine dispensing aperture, or a sponge like dispensing conduit, or include other means which permits controlled dispensing of the liquid, which otherwise may run too freely from its container. Other means necessary to instil a gel or ointment may be used. For example, the neat liquid or gel can be dropped into the inferior cul-de-sac, the space between the eyeball and eyelid, by tilting the head back and gently pulling down the inferior palpebral conjunctiva until a "V" pocket is formed between the eye and the inferior eyelid, whereupon the liquid or gel can be instilled into the "V" pocket. The objective is to instill the neat liquid or gel into the inferior formix of the inferior cul-de-sac. Because of the density, viscosity, and immiscibility of the perfluorocarbons, such liquids will sink to and remain at the inferior formix. The mechanism of blinking will then act to disperse the liquids across the corneal and conjunctiva surfaces. The liquids, as a direct result of their immiscibility, will usually disperse as "microemulsions" rather than solutions. Microemulsions will be dispersed within the lipid layer of the preocular tear film acting to lubricate and wet the epithelial surfaces with a substantial amount remaining in the cul-de-sacs for significant periods of time being available for continuous dispersion. The significant retention of the liquids within the cul-de-sacs occurs as a result of their immiscibility, density and viscosity.

The eye utilizes the mechanism of blinking to not only spread the fluids therein, but also to eliminate such fluids by way of the lacrimal canaliculi. That is, the drainage of fluid, such as tears, does not depend upon gravity for its elimination, but rather, the

fluid enters the puncta and passes along the lacrimal canaliculi by capillary attraction aided by aspiration caused by a contraction of muscle embedded within the eyelids. When the eyelids are partially closed, as in

5 the initial phase of blinking, contraction of the muscles causes the puncta to close. The canaliculi are then compressed while the lacrimal sac is dilated when the eyelids are further closed. Fluid, thus, is aspirated into the sac and forced down the nasolacrimal duct toward its aperture into the nose. When a perfluorocarbon liquid is dropped into the eye, the mechanism of blinking is less efficient in its elimination. This effect is due to the density, viscosity, and immiscibility of these liquids which act

10 to antagonize the aspiration effect of blinking, retarding their expulsion. Perfluorocarbon liquids, as extraocular ophthalmology preparations, are beneficial for treating infections, cornea transplants or repairs, and dry eyes and tear abnormalities such as aqueous tear

15 deficiency, tear film instability, surfacing problems, effects or agents, and tear film drainage. Upon dispersion of the perfluorocarbon liquids across the corneal and conjunctiva surfaces, the microemulsions are dispersed within the lipid or outermost layer of the tear

20 film where it will primarily demonstrate its effect. There should be little if no adverse effects on the mucin layer, as seen with ointments, when such liquids are instilled. Thus, the instillation of perfluorocarbon liquids as extraocular ophthalmology preparations will

25 provide a lubricating, wetting or protecting surface without interfering with mucin adsorption onto the corneal and conjunctiva surfaces. Thus, the liquids will not only provide these beneficial effects on the pre-ocular tear film, but will remain within the cul-de-

30 sacs for longer periods of time as a result of their immiscibility, density and viscosity. In contrast to

these advantageous liquid perfluorocarbons, the present ocular lubricants, comprising solutions of hydroxypropyl methylcellulose, polyvinyl alcohol, polyvinyl pyrrolidone soluble polymers, dextran and mixtures

5 thereof, are rapidly cleared from the eye requiring frequent administration.

No preservatives are necessary to maintain sterility in the preferred preparations of the invention because neat liquid perfluorocarbons are nonaqueous.

10 Furthermore, in the case of polyfluoroolefin polymers or copolymers, contact lenses may be fabricated which are autoclavable or may be treated by other harsh chemical methods to maintain sterility. Thus, the microvilli within the epithelial of the cornea are not
15 adversely effected, as exhibited by present extraocular ophthalmology preparations, and the adsorption of mucin onto the microvilli remain intact. Since the liquids are non-aqueous, the pH or isotonicity does not have to be considered to avoid irritation and stinging upon
20 their instillation. With contact lenses, the liquids can be employed as protective, wetting, lubricating and oxygenating extraocular ophthalmic preparations. The irritation and possible superficial vascularization and opacification of the cornea will also be reduced. In
25 corneal epithelial diseases, such as corneal ulcers, recurrent corneal erosion and marginal corneal ulcers, the liquid perfluorocarbon preparations will decrease the incidence of corneal vascularization, scarring and opacification as seen with such corneal disorders.
30 Likewise, in corneal repair and/or transplantation, the application of perfluorocarbon liquids during and after such procedures should decrease or eliminate the untoward side effects of corneal vascularization, scarring and opacification. It is the oxygen-carrying
35 property of the liquid perfluorocarbons as well as their nonaqueous, viscous, and dense properties that make them ideal liquids to treat such procedures.

Due to the retention of perfluorocarbon liquids within the cul-de-sacs for considerable periods of time, such liquids can be employed as suitable vehicles for other substances, such as pharmaceuticals to treat

5 extraocular and intraocular disorders. Presently drops, ointments, and ocular inserts are utilized to deliver drugs extraocularly. As stated above, solutions are readily excreted, suspensions are irritating, ointments blur vision and interfere with
10 mucin adsorption, while ocular inserts are uncomfortable and subject to rupture or loss. With the use of liquid perfluorocarbons as vehicles, the number of administrations can be reduced while the adverse effects of ointments, suspensions and inserts can be eliminated.

15 In view of the above description, it is apparent that other perfluorocarbon solids, liquids or gels are suitable for use in accordance with the principles of this invention. Furthermore, it is apparent that perfluorocarbon liquids and derivatives
20 thereof are unique and advantageous liquids when used in extraocular ophthalmological preparations. The invention, its principles and objectives will be further understood in view of the following examples with reference to the drawings which are anatomical
25 illustrations of the eye. Fig. 1 constitutes a vertical section of the eye illustrating the eyelid, and the external and internal components of the eye. As stated, the secretory components of the eye secrete the preocular tear film which is comprised of three layers.
30 The oil layer originates from the meibomian glands and glands of Zeis, the aqueous layer is produced by the lacrimal and accessory lacrimal (Wolfring's and Krause) glands, while mucin is secreted by the goblet cells (not illustrated) which are scattered over the palpebral conjunctiva. The superior and inferior fornix
35 constitute the deposit area within the superior and

inferior cul-de-sacs. The middle layer, the tear fluid, is aqueous and provides hydration, antibacterial agents and nutritional elements to the external surfaces. The innermost layer of the tear film comprises mucin which 5 covers the conjunctiva and corneal surfaces. Mucin functions to permit the overlying aqueous layer to spread across the surfaces. Herein the term "external surface" of the eye is meant to include broadly all such surfaces shown in the drawing and referred to herein 10 which may come into direct contact with liquid which is introduced between an eyelid and eyeball.

Fig. 2 illustrates the excretory apparatus employed by the eye to eliminate fluids therein. The puncta are the apertures leading into the lacrimal 15 canaliculus and eventually into the nasal lacrimal duct.

EXAMPLE I

A single drop from a 3 ml syringe and a 25 gauge needle containing perfluoro 1-methyldecalin (PP9) was instilled, ie placed into each eye of a rabbit.

20 The rabbit was observed for a period of two hours through a Codman-Mentor Operating Microscope. Specifically, the examination of the rabbit cornea showed no evidence of corneal toxicity as manifested by the lack of epithelial staining and maintenance of 25 corneal transparency. Also, there was no inflammation or irritation observed in the bulbar or palpebral conjunctiva. Further, the rabbit demonstrated no abnormal visual responses.

EXAMPLE II

30 A single drop containing perfluoro-1-methyl-decalin (PP9), was instilled into the right eye of a human. The instillation, using a plastic dropper bottle, was made onto the cornea of the right eye. Prior to and after instilling the liquid, various tests 35 including Visual Acuity, Corneal Sensitivity, Anterior Segment Examination with and without Fluorescein, and

Tear Film stability were conducted for comparative purposes. No negative effects or results were found before or after the instillation of the perfluoro-1-methyldecalin. Thus, the results demonstrated that
5 the eye remained unchanged after the experiment. The subject's visual acuity, as measured before and after, was 20/20 corrected. There was no change in his corneal sensitivity. The slit-lamp biomicroscopy test with and without fluorescein detected no corneal ulcers,
10 irritations or drying cells on his ocular surface. The subject's tear stability or break-up time, also measured before and after, remained the same at 25 seconds. Furthermore, the subject experienced no gritty, stinging, or burning sensations, or excess
15 mucous secretions from the instilled liquid. The subject found the liquid to be comfortable, soothing and did not interfere with his blinking or vision. The liquid was detected in his eye for up to an hour after it had been instilled. Finally, there were no ocular,
20 nasal, or gastrointestinal side effects experienced by the subject.

EXAMPLE III

A circle of TEFLON FEP by duPont was cut to provide a lens having an approximate diameter of 1/2
25 inch and a thickness of approximately 3 mils. As mentioned above, TEFLON FEP is a transparent polymer of polyfluoroethylene-propylene and the film used in this example was transparent, soft and pliable. Two rabbits were then anesthetized with Ketamine and circles of
30 TEFLON were placed on the rabbits' eyes under the lids and thereafter two stitches were placed through the eyelids to close the eyes. On the day after the insertion of the perfluoroethylene-propylene lenses, both rabbits appeared healthy. On later examination of
35 the eyes, there was no damage observable to the corneas. The intent of this experiment was to leave the polymeric

film in the eyes as long as possible and after perhaps a few days the films had fallen out but, again, no damage was observable in the eyes of the rabbits. Several months afterwards, the rabbits' eyes appeared 5 to be in perfect condition. The TEFLON FEP provides oxygen and carbon dioxide permeability at a high rate. It is well known that a human cornea requires oxygen in order to remain vital. Thus, the perfluorocarbon lens of this example provides high oxygen permeability 10 to maintain the vitality of the cornea. In addition, liquid perfluorocarbons such as perfluoromethyl decalin have been employed as lubricants along with FEP TEFLON lenses.

EXAMPLE IV

15 A rabbit, having a *Pasturella* infection in his right eye was treated with an extraocular ophthalmologic perfluorocarbon preparation according to this invention. The rabbit was treated on Days 0, 1, 3, 6 and until Day 7 by dropping a therapeutic ophthalmic emulsion 20 containing PP9 (perfluoromethyl decalin identified above) as an antibiotic and antifungal preparation. The composition of the therapeutic ophthalmic solution was 10 cc PP9, 10 cc PANALOG, 10 cc sterile water and 30 cc pluronic F68 (8 g/dl). The mixture was 25 sonicated to make a white gel emulsion. PANALOG (Squibb) is a nystatin, neomycin sulfate, thiostrepton, triamcinolone acetonide ointment. Each ml contains nystatin (100,000 units), neomycin sulfate equivalent to neomycin base (2.5 mg), thiostrepton (2,500 units), 30 triamcinolone acetonide (1 mg in PLASTIBASE (plasticized hydrocarbon gel), a polyethylene and mineral oil gel base.

After 7 days of treatment, the infection caused by the *Pasturella* was completely gone. 35 Photographs and cultures were taken on day 7 and it was observed that there was some redness of the conjunctiva

0112658

24-

which was minor. The emulsion preparation herein could be improved by pH and ionic adjustment if desired.

In view of the above detailed description and examples, other modifications will become apparent to
5 those of ordinary skill in the art to which this invention pertains.

1-

CLAIMS:

1. An ophthalmologic method which comprises extraocularly treating the eye with a perfluorocarbon or substituted derivative thereof.
2. The method of Claim 1, wherein the perfluorocarbon comprises a gel or a liquid
3. The method of Claim 2, wherein said perfluorocarbon or substituted derivative thereof is in a physical state selected from a neat liquid, an emulsion, a gel, a solution or a suspension.
4. The method of Claim 3, wherein said perfluorocarbon comprises a liquid emulsified in water.
5. The method of any one of Claims 2-4, wherein said liquid is a perfluorocyclocarbon.
6. The method of Claim 5, wherein said perfluorocyclocarbon is selected from perfluoro(methylcyclohexane), perfluoro(1,3-dimethylcyclohexane), perfluoro(decahydronaphthalene), perfluoro(decahydro-1-methylnaphthalene), perfluoro(decahydromethylnaphthalene), perfluorodimethyladamantane, perfluorotrimethylbicyclo[3.3.1.]nonane, perfluorotetrahydromethylclopentadiene, perfluorobicyclo[5.3.0.]decane and perfluorodimethylbicyclo[3.3.1.]nonane, perfluoroctyl bromide, perfluoro 1-bromobutylisopropyl ether, and mixtures thereof.
7. The method of Claim 6, wherein said liquid is perfluoro-1-methyldecalin.
8. The method of any one of Claims 2-7, wherein said liquid also contains a pharmaceutical agent.
9. An ophthalmologic method of any one of Claims 2-8, wherein said liquid is instilled into an eye extraocularly.
10. The method of Claim 1, wherein said perfluorocarbon is in the form of a film to serve as a contact lens.

11. The method of Claim 10, wherein said perfluorocarbon is a polyfluoro olefin.

12. The method of Claim 11, wherein the polyfluoro olefin is a transparent polyfluoroethylene-propylene polymer film.

13. A polyfluorocarbon or substituted derivative thereof in the form of a gel.

14. A gel of Claim 13, wherein said perfluorocarbon is a perfluorocyclocarbon.

15. A gel of Claim 14, wherein said perfluorocyclocarbon is selected from perfluoro(methylcyclohexane), perfluoro(1,3-dimethylcyclohexane), perfluoro(decahydronaphthalene), perfluoro(decahydro-1-methylnaphthalene), perfluoro(decahydromethyl-naphthalene), perfluorodimethyladamantane, perfluoro-trimethylbicyclo[3.3.1.]nonane, perfluorotetrahydro-dicyclopentadiene, perfluorobicyclo[5.3.0.]decane and perfluorodimethylbicyclo[3.3.1.]nonane, perfluoroctyl bromide, perfluoro 1-bromobutylisopropyl ether, and mixtures thereof.

16. An extraocular prosthesis comprising a perfluorocarbon or substituted derivative therein in a physical state selected from a solid or gel.

17. The extraocular prosthesis of Claim 16, wherein said prosthesis has a sufficient refractive index to correct an optical acuity.

18. The extraocular prosthesis of Claim 16 or 17, wherein said prosthesis is a contact lens.

19. The extraocular prosthesis of Claim 16, wherein said prosthesis is adapted for cosmetic purposes.

20. A contact lens of Claim 18, wherein said perfluorocarbon is perfluoroethylene-propylene polymer.

21. The method of Claim 16, wherein said prosthesis is a bandage.

22. The method of Claim 21, wherein said bandage permits movement of pharmaceutical fluids to

permeate through said bandage to the eye, as well as under said bandage.

23. The method of Claim 21 or Claim 22, wherein said bandage increases duration and/or degree of the effect from a pharmaceutical agent.

24. An ophthalmological method which comprises extraocularly treating disorders of the eye with a prosthesis of any one of Claims 16-23.

25. A device for the extraocular treatment of an eye of an animal, comprising a container, a perfluorocarbon or substituted derivative thereof in liquid form within the container, and means for dispensing controlled amounts of said liquid perfluorocarbon or substituted derivative thereof extraocularly onto the eye to be treated.

26. A device of Claim 25, wherein said liquid is a perfluorocyclocarbon.

27. A device of Claim 26, wherein said perfluorocyclocarbon is selected from perfluoro(methylcyclohexane), perfluoro(1,3-dimethylcyclohexane), perfluoro(decahydronaphthalene), perfluoro(decahydro-1-methylnaphthalene), perfluoro(decahydromethyl-naphthalene), perfluorodimethyladamantane, perfluorotrimethylbicyclo[3.3.1.]nonane, perfluorotetrahydro-dicyclopentadiene, perfluorobicyclo[5.3.0.]decane and perfluorodimethylbicyclo[3.3.1.]nonane, perfluoroctyl bromide, perfluoro 1-bromobutylisopropyl ether, and mixtures thereof.

28. A device of any one of Claims 25-27, constructed in the form of an eye dropper.

0112658

Fig. 1.




Fig. 2.

